Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 3 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 12378231

    Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof

    APOGEE PHARMACEUTICALS, INC. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  2. US 12378245

    Crystalline forms of an RSK inhibitor

    PHOENIX MOLECULAR DESIGNS · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  3. US 12378241

    Pyridine derivative as FGFR and VEGFR dual inhibitors

    CGeneTech (Suzhou, China) CO., Ltd. · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  4. US 12377078

    Viral inhibitors, the synthesis thereof, and intermediates thereto

    Takeda Pharmaceutical Company Limited · Granted Aug 5, 2025 · Expires Jul 31, 2045

    granted
  5. CN 120418289

    Combination therapy of bispecific binding agents that bind to CLDN18.2 and CD3 with immune checkpoint inhibitors

    ASTELLAS PHARMA EUROPE B V · Granted Aug 1, 2025 · Expires Jul 27, 2045

    granted
  6. US 12371434

    MLL1 inhibitors and anti-cancer agents

    CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  7. US 12370194

    Metalloenzyme inhibitor compounds

    Eikonizo Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  8. US 12370195

    Oral compositions of MK2 pathway inhibitor for treatment of immune conditions

    Aclaris Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  9. US 12371435

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  10. US 12364688

    NSD family inhibitors and methods of treatment therewith

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  11. US 12365664

    Small molecule inhibitors of SRC tyrosine kinase

    The Board of Regents of the University of Texas System · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  12. US 12365688

    Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors

    Revolution Medicines, Inc. · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  13. US 12365653

    Small molecule inhibitors of lactate dehydrogenase and methods of use thereof

    THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  14. US 12365659

    Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Jul 22, 2025 · Expires Jul 17, 2045

    granted
  15. US 12357650

    Methods and compositions for cancer therapies that include delivery of halogenated thymidines and thymidine phosphorlylase inhibitors in combination with radiation

    Shuttle Pharmaceuticals, Inc. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  16. US 12358896

    LRRK2 inhibitors and methods of making and using thereof

    DENALI THERAPEUTICS INC. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  17. US 12358931

    3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl) propanenitrile as a JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  18. US 12358892

    Metalloenzyme inhibitors for treating cancers, Alzheimer's disease, hemochromatosis, and other disorders

    Miralogx LLC · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  19. US 12351587

    Bicyclic compound as RIP-1 kinase inhibitor and application thereof

    Medshine Discovery Inc. · Granted Jul 8, 2025 · Expires Jul 3, 2045

    granted
  20. US 12343380

    Expansion of TILs utilizing AKT pathways inhibitors

    Iovance Biotherapeutics, Inc. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  21. US 12344585

    Crystalline salts of a plasma kallikrein inhibitor

    BioCryst Pharmaceuticals, Inc. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  22. US 12336976

    Glutaminase inhibitor therapy

    The Board of Regents of the University of Texas System · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  23. US 12338242

    TYK2 inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  24. US 12331058

    SHP2 and CDK4/6 dual-target inhibitory compound and pharmaceutical composition containing the same

    CHINA PHARMACEUTICAL UNIVERSITY · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted